Xenogeneic PSA Vaccine for Prostate Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, especially for metastatic disease, are limited in effectiveness, and existing immunotherapy approaches face challenges in inducing robust immune responses against self-antigens like PSA, which are weakly immunogenic and difficult to target effectively.
Innovation Solution
A xenogeneic PSA antigen from non-human primates with amino acid homology between 88% to 98% similarity to human PSA is used in a vaccine, molecularly altered to optimize immune response, administered with a DNA vaccine expressing the non-human primate PSA sequence to induce cytotoxic cell-mediated immunity against human PSA-producing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human PSA is used as a vaccine antigen, then the vaccine targets the correct self-antigen, but the immune response is weak because PSA is a self-antigen and weakly immunogenic
Solution Approach 1:
The patent uses xenogeneic PSA (from non-human primates) as an intermediary antigen that structurally resembles human PSA but is sufficiently different to be recognized as foreign by the human immune system. This intermediary approach allows the vaccine to stimulate strong immune responses while still targeting human PSA-expressing cancer cells through cross-reactivity
Solution Approach 2:
The patent modifies the antigen source parameter by transitioning from human PSA to xenogeneic PSA (specifically from chimpanzees, gorillas, or orangutans). This parameter change maintains structural homology (80-95% amino acid sequence identity) while altering immunogenicity properties to elicit stronger immune responses
2Productivity
If xenogeneic PSA is used to strengthen immune response, then immunogenicity is improved, but there is risk of not effectively targeting human PSA due to sequence differences
Solution Approach 1:
The patent carefully selects xenogeneic PSA sources (chimpanzee, gorilla, orangutan) that maintain 80-95% amino acid sequence identity to human PSA. This controlled parameter change optimizes the balance between immunogenicity (sufficient difference to trigger immune response) and cross-reactivity (sufficient similarity to target human PSA-expressing cells)
Solution Approach 2:
The patent focuses on preserving critical local regions of PSA that are essential for both immune recognition and functional activity. By maintaining key structural and functional domains while allowing variations in less critical regions, the vaccine achieves both strong immune stimulation and effective targeting of human cancer cells
3Ease of manufacture
If traditional hormonal therapies are used for metastatic prostate cancer, then treatment is available, but effectiveness is limited and only transient
Solution Approach 1:
The patent replaces hormonal therapy (chemical/biochemical system) with immunotherapy (biological immune system). Instead of using hormones to block androgen receptors, the vaccine harnesses the patient's own immune system to recognize and destroy PSA-expressing cancer cells, providing a fundamentally different mechanism of action that may overcome resistance to hormonal therapies
Data Source
AI summary
An object of the invention is to provide methods and compositions relating to a vaccine against prostate cancer which includes a non-human-primate PSA for administration to humans to provide an immune response against human PSA. More generally, an object of the invention is to provide methods and compositions relating to using a non-human primate xenogeneic antigen (e.g. protein) in a human, wherein, with respect to the non-human primate xenogeneic antigen that is used, there are relatively few interspecies differences between the non-human primate xenogeneic antigen and the human self antigen in order to induce an optimal immune response in the human to its native self antigen.